

Ref: FOI/GS/ID 9243

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

06 August 2024

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Diffuse Large B Cell Lymphoma (DLBCL).

You asked: All questions are shown as received by the Trust.

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- a. R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)*
- b. R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)*
- c. Pola-BR (polatuzumab vedotin with rituximab and bendamustine)*
- d. Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)*
- e. R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)*
- f. R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)*
- g. Axicabtagene ciloleucel (Yescarta)*
- h. Tisagenlecleucel*
- i. Epcoritamab*
- j. Loncastuximab tesirine*
- k. Glofitamab*
- l. Any other SACT*
- m. Stem cell transplant or bone marrow transplant (autologous or allogeneic)*

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- a. Axicabtagene ciloleucel (Yescarta)
- b. Tisagenlecleucel
- c. Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
- d. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- e. Any other treatments

Q4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

- a. CAR-T Therapy (E.g. Axicabtagene ciloleucel)
- b. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- c. Any other treatment

Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?

Trust response:

Q1. In period 1/1/24 to 30/6/24 this was 21 patients.

Q1a. Of the patients above, 12 had a treatment in the same date period.

Q2.

a.	5
b.	11
c.	4
d.	14
e.	0
f.	0
g.	0
h.	0
i.	0
j.	0
k.	0
l.	13
m.	0

Q3. The Trust does not record this data.

Q4. Zero for January to June 2024

Q5. None at this time.